Article Detail - JD DME
July 2023 HCPCS Updates
CMS has released the July 2023 Healthcare Common Procedure Coding System (HCPCS) File. Inclusion on this list does not indicate coverage. All HCPCS code changes are effective and should be used for claims with dates of service on or after July 1, 2023. Please watch the Noridian website for additional policy updates regarding HCPCS codes.
Added HCPCS Codes
Effective for dates of service on and after July 1, 2023
HCPCS | Description |
---|---|
J0137 | Injection, acetaminophen (hikma) not therapeutically equivalent to j0131, 10 mg |
J0206 | Injection, allopurinol sodium, 1 mg |
J0216 | Injection, alfentanil hydrochloride, 500 micrograms |
J0457 | Injection, aztreonam, 100 mg |
J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg |
J0736 | Injection, clindamycin phosphate, 300 mg |
J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg |
J1576 | Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg |
J1805 | Injection, esmolol hydrochloride, 10 mg |
J1806 | Injection, esmolol hydrochloride (wg critical care) not therapeutically equivalent to j1805, 10 mg |
J1811 | Insulin (fiasp) for administration through dme (i.e., insulin pump) per 50 units |
J1812 | Insulin (fiasp), per 5 units |
J1813 | Insulin (lyumjev) for administration through dme (i.e., insulin pump) per 50 units |
J1814 | Insulin (lyumjev), per 5 units |
J1836 | Injection, metronidazole, 10 mg |
J1920 | Injection, labetalol hydrochloride, 5 mg |
J1921 | Injection, labetalol hydrochloride (hikma) not therapeutically equivalent to j1820, 5 mg |
J1941 | Injection, furosemide (furoscix), 20 mg |
J1961 | Injection, lenacapavir, 1 mg |
J2249 | Injection, remimazolam, 1 mg |
J2305 | Injection, nitroglycerin, 5 mg |
J2329 | Injection, ublituximab-xiiy, 1mg |
J2371 | Injection, phenylephrine hydrochloride, 20 micrograms |
J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms |
J2427 | Injection, paliperidone palmitate extended release (invega hafyera, or invega trinza), 1 mg |
J2561 | Injection, phenobarbital sodium (sezaby), 1 mg |
J2598 | Injection, vasopressin, 1 unit |
J2599 | Injection, vasopressin (american regent) not therapeutically equivalent to j2598, 1 unit |
J2806 | Injection, sincalide (maia) not therapeutically equivalent to j2805, 5 micrograms |
J9029 | Injection, nadofaragene firadenovec-vncg, per therapeutic dose |
J9056 | Injection, bendamustine hydrochloride (vivimusta), 1 mg |
J9058 | Injection, bendamustine hydrochloride (apotex), 1 mg |
J9059 | Injection, bendamustine hydrochloride (baxter), 1 mg |
J9063 | Injection, mirvetuximab soravtansine-gynx, 1 mg |
J9259 | Injection, paclitaxel protein-bound particles (american regent) not therapeutically equivalent to j9264, 1 mg |
J9322 | Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg |
J9323 | Injection, pemetrexed (hospira) not therapeutically equivalent to j9305, 10 mg |
J9347 | Injection, tremelimumab-actl, 1 mg |
J9350 | Injection, mosunetuzumab-axgb, 1 mg |
J9380 | Injection, teclistamab-cqyv, 0.5 mg |
J9381 | Injection, teplizumab-mzwv, 5 mcg |
Q5131 | Injection, adalimumab-aacf (idacio), biosimilar, 20 mg |
Deleted HCPCS Code
Invalid for billing for dates of service July 1, 2023 and after
HCPCS | Description |
---|---|
J2370 | INJECTION, PHENYLEPHRINE HCL, UP TO 1 ML |
Description Update
The long description of the HCPCS code has been updated as of July 1, 2023
HCPCS | Description |
---|---|
J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg |